Sol Gel Technologies LtdNASDAQ:SLGLNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7500
- TODAY'S CHANGE (%)-0.0200 (-2.5974%)
- Bid / Lots0.7500/ 10
- Ask / Lots0.8100/ 2
- Open / Previous Close0.7800 / 0.7700
- Day Range
- 52 Week Range
- Volume4,954
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLGL |
|---|---|---|
| 10:08 ET | 3680 | 0.7501 |
| 10:15 ET | 100 | 0.7501 |
| 10:32 ET | 100 | 0.75 |
| 11:04 ET | 370 | 0.81 |
| 11:22 ET | 100 | 0.75 |
| 12:41 ET | 100 | 0.81 |
| 12:59 ET | 100 | 0.75 |
May 28, 2024
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
May 22, 2024
DJ Sol-Gel Technologies Price Target Maintained With a $6.00/Share by HC Wainwright & Co., from 7:51AM ET on Wednesday May 22, 2024 by Dow Jones
7:51AM ET on Wednesday May 22, 2024 by Dow Jones
May 20, 2024
DJ Sol-Gel Technologies Is Maintained at Buy by HC Wainwright & Co., from 7:34AM ET on Monday May 20, 2024 by Dow Jones
7:34AM ET on Monday May 20, 2024 by Dow JonesPress Release: Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates, from 7:00AM ET on Monday May 20, 2024 by Dow Jones
7:00AM ET on Monday May 20, 2024 by Dow JonesSol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates, from 7:00AM ET on Monday May 20, 2024 by Dow Jones
7:00AM ET on Monday May 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Sol Gel Technologies Ltd | 22.7M | -0.9x | --- |
Nanopharmaceutics Inc | 22.3M | -29.8x | --- |
Lyra Therapeutics Inc | 19.5M | -0.2x | --- |
Lumos Pharma Inc | 20.1M | -0.5x | --- |
Oncternal Therapeutics Inc | 24.3M | -0.7x | --- |
Aprea Therapeutics Inc | 24.4M | -1.3x | --- |
Company Information
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
Contact Information
- Headquarters
- Golda Meir 7NESS-ZIONA, Israel 7403650
- Phone
- ---
- Fax
- ---
Executives
- Executive Chairman of the Board
- Moshe Arkin
- Chief Executive Officer, Co-Founder, Director
- Alon Seri-Levy
- Chief Financial Officer
- Gilad Mamlok
- Vice President - Operations
- Itzik Yosef
- Vice President - Quality
- Nissim Bilman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.7M |
|---|---|
Revenue (TTM) | $1.7M |
Shares Outstanding | 27.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.53 |
EPS | $-0.82 |
Book Value | $1.39 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 13.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,450.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
